Generic placeholder image

Infectious Disorders - Drug Targets

Author(s): Sushen Singh Choudhary and Sushma Verma*

DOI: 10.2174/0118715265270311231113041807

DownloadDownload PDF Flyer Cite As
A Comprehensive Review on Patents, Herbal Treatment and Clinical Trials on Acquired Immune Deficiency Syndrome

Article ID: e201123223654 Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

This paper provides an outline of the Human immunodeficiency virus (HIV), its mechanism of action, and types of HIV/AIDS. Additionally, it offers recent advances and patent data on HIV medications and formulations for the last ten years. The HIV/AIDS patents describes how compounds can stop viruses from spreading and stop HIV from multiplying. It also gives information about monolithic tablets, fixed oral doses of triple HIV formulations, and drug delivery systems that use electrospun fibers. The patents also reveals the treatment for patients having liver disease by using herbal ingredients. The effects of various herbal ingredients and preparations on HIV replication, immunological function, and symptom management have been researched. Despite the encouraging randomized trial data available, it is crucial to proceed cautiously when using herbal treatments for HIV/AIDS treatment. Recent years clinical trials of HIV/AIDS were also reviewed. Herbal remedies are preferred more than other drugs because they have fewer side effects and have long-lasting effects for the treatment of HIV/AIDS. The regulation, quality assurance, and standardization of herbal products are the challenges for the industry.

Graphical Abstract

[1]
Jin, H.; Chong, H.; Zhu, Y.; Zhang, M.; Li, X.; Bazybek, N.; Wei, Y.; Gong, F.; He, Y.; Ma, G. Preparation and evaluation of amphipathic lipopeptide-loaded PLGA microspheres as sustained-release system for AIDS prevention. Eng. Life Sci., 2020, 20(11), 476-484.
[http://dx.doi.org/10.1002/elsc.202000026] [PMID: 33204234]
[2]
Jenita, J.; Wilson, B.; Chocalingam, V. Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug-Efavirenz. Int. J. Pharm. Investig., 2014, 4(3), 142-148.
[http://dx.doi.org/10.4103/2230-973X.138348] [PMID: 25126528]
[3]
Ghosh, A.K.; Osswald, H.L.; Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem., 2016, 59(11), 5172-5208.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01697] [PMID: 26799988]
[4]
Piot, P.; Abdool Karim, S.S.; Hecht, R.; Legido-Quigley, H.; Buse, K.; Stover, J.; Resch, S.; Ryckman, T.; Møgedal, S.; Dybul, M.; Goosby, E.; Watts, C.; Kilonzo, N.; McManus, J.; Sidibé, M. Defeating AIDS-advancing global health. Lancet, 2015, 386(9989), 171-218.
[http://dx.doi.org/10.1016/S0140-6736(15)60658-4] [PMID: 26117719]
[5]
Silverberg, M.J.; Lau, B.; Achenbach, C.J.; Jing, Y.; Althoff, K.N.; D’Souza, G.; Engels, E.A.; Hessol, N.A.; Brooks, J.T.; Burchell, A.N.; Gill, M.J.; Goedert, J.J.; Hogg, R.; Horberg, M.A.; Kirk, G.D.; Kitahata, M.M.; Korthuis, P.T.; Mathews, W.C.; Mayor, A.; Modur, S.P.; Napravnik, S.; Novak, R.M.; Patel, P.; Rachlis, A.R.; Sterling, T.R.; Willig, J.H.; Justice, A.C.; Moore, R.D.; Dubrow, R. Cumulative incidence of cancer among persons with HIV in North America: A cohort study. Ann. Intern. Med., 2015, 163(7), 507-518.
[http://dx.doi.org/10.7326/M14-2768] [PMID: 26436616]
[6]
Flexner, C.; Thomas, D.L.; Swindells, S. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. Curr. Opin. HIV AIDS, 2019, 14(1), 13-20.
[http://dx.doi.org/10.1097/COH.0000000000000510] [PMID: 30394948]
[7]
Uckun, FM; Qazi, S; Venkatachalam, TK In vitro anti-HIV potency of Stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung., 2005, 55(4), 223.
[8]
Cattaneo, D.; Andreoni, M.; Carosi, G.; Cauda, R.; Lazzarin, A.; Rizzardini, G. Generic antiretrovirals for the treatment of HIV: A novel challenge for Western countries?. Int. J. Clin. Pharmacol. Ther., 2017, 55(5), 381-393.
[http://dx.doi.org/10.5414/CP202775] [PMID: 28211784]
[9]
Napper, L.E.; Fisher, D.G.; Reynolds, G.L.; Johnson, M.E. HIV risk behavior self-report reliability at different recall periods. AIDS Behav., 2010, 14(1), 152-161.
[http://dx.doi.org/10.1007/s10461-009-9575-5] [PMID: 19475504]
[10]
Vickers, A. Recent advances: Complementary medicine. BMJ, 2000, 321(7262), 683-686.
[http://dx.doi.org/10.1136/bmj.321.7262.683] [PMID: 10987776]
[11]
Özsoy, M.; Ernst, E. How effective are complementary therapies for HIV and AIDs?--A systematic review. Int. J. STD AIDS, 1999, 10(10), 629-635.
[http://dx.doi.org/10.1258/0956462991913088] [PMID: 10582628]
[12]
Nyamweya, S.; Hegedus, A.; Jaye, A.; Rowland-Jones, S.; Flanagan, K.L.; Macallan, D.C. Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Rev. Med. Virol., 2013, 23(4), 221-240.
[http://dx.doi.org/10.1002/rmv.1739] [PMID: 23444290]
[13]
Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS Pandemic. Cold Spring Harb. Perspect. Med., 2011, 1(1), a006841.
[http://dx.doi.org/10.1101/cshperspect.a006841] [PMID: 22229120]
[14]
Esbjörnsson, J.; Månsson, F.; Kvist, A.; Isberg, P.E.; Nowroozalizadeh, S.; Biague, A.J.; da Silva, Z.J.; Jansson, M.; Fenyö, E.M.; Norrgren, H.; Medstrand, P. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N. Engl. J. Med., 2012, 367(3), 224-232.
[http://dx.doi.org/10.1056/NEJMoa1113244] [PMID: 22808957]
[15]
Peterson, K.; Ruelle, J.; Vekemans, M.; Siegal, F.P.; Deayton, J.R.; Colebunders, R. The role of raltegravir in the treatment of HIV-2 infections: Evidence from a case series. Antivir. Ther., 2012, 17(6), 1097-1100.
[http://dx.doi.org/10.3851/IMP2303] [PMID: 22892365]
[16]
Peterson, K.; Jallow, S.; Rowland-Jones, S.L.; de Silva, T.I. Antiretroviral therapy for HIV-2 infection: Recommendations for management in low-resource settings. Aids Res. Treat., 2011, 2011, 1-11.
[http://dx.doi.org/10.1155/2011/463704] [PMID: 21490779]
[17]
Campbell-Yesufu, O.T.; Gandhi, R.T. Update on human immunodeficiency virus (HIV)-2 infection. Clin. Infect. Dis., 2011, 52(6), 780-787.
[http://dx.doi.org/10.1093/cid/ciq248] [PMID: 21367732]
[18]
Chen, B. Molecular mechanism of HIV-1 entry. Trends Microbiol., 2019, 27(10), 878-891.
[http://dx.doi.org/10.1016/j.tim.2019.06.002] [PMID: 31262533]
[19]
Harrison, S.C. Mechanism of membrane fusion by viral envelope proteins. Adv. Virus Res., 2005, 64, 231-261.
[http://dx.doi.org/10.1016/S0065-3527(05)64007-9] [PMID: 16139596]
[20]
Yang, S.S.; Cragg, G.M.; Newman, D.J.; Bader, J.P. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J. Nat. Prod., 2001, 64(2), 265-277.
[http://dx.doi.org/10.1021/np0003995] [PMID: 11430019]
[21]
Ashe, S.; Nayak, D.; Tiwari, G.; Rauta, P.R.; Nayak, B. Development of liposome-encapsulated ketoconazole: Formulation, characterisation and evaluation of pharmacological therapeutic efficacy. Micro & Nano Lett., 2015, 10(2), 126-129.
[http://dx.doi.org/10.1049/mnl.2014.0198]
[22]
Elzoghby, A.O. Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research. J. Control. Release, 2013, 172(3), 1075-1091.
[http://dx.doi.org/10.1016/j.jconrel.2013.09.019] [PMID: 24096021]
[23]
Nayak, D.; Boxi, A.; Ashe, S.; Thathapudi, N.C.; Nayak, B. Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation. Mater. Sci. Eng. C, 2017, 73, 406-416.
[http://dx.doi.org/10.1016/j.msec.2016.12.073] [PMID: 28183626]
[24]
Magnus, C.; Regoes, R.R. Restricted occupancy models for neutralization of HIV virions and populations. J. Theor. Biol., 2011, 283(1), 192-202.
[http://dx.doi.org/10.1016/j.jtbi.2011.06.004] [PMID: 21683711]
[25]
Ogunlaran, O.M.; Oukouomi Noutchie, S.C. Mathematical model for an effective management of HIV infection. BioMed Res. Int., 2016, 2016, 1-6.
[http://dx.doi.org/10.1155/2016/4217548] [PMID: 27057541]
[26]
Curley, P.; Liptrott, N.J.; Owen, A. Advances in nanomedicine drug delivery applications for HIV therapy. Future Sci. OA, 2018, 4(1), FSO230.
[http://dx.doi.org/10.4155/fsoa-2017-0069] [PMID: 29255619]
[27]
Zazo, H.; Colino, C.I.; Lanao, J.M. Current applications of nanoparticles in infectious diseases. J. Control. Release, 2016, 224, 86-102.
[http://dx.doi.org/10.1016/j.jconrel.2016.01.008] [PMID: 26772877]
[28]
Tekade, R.K.; Maheshwari, R.; Soni, N.; Tekade, M.; Chougule, M.B. Nanotechnology for the development of nanomedicine.Nanotechnology-based approaches for targeting and delivery of drugs and genes; Elsevier, Inc, 2017, pp. 3-61.
[http://dx.doi.org/10.1016/B978-0-12-809717-5.00001-4]
[29]
Caldera, F.; Tannous, M.; Cavalli, R.; Zanetti, M.; Trotta, F. Evolution of cyclodextrin nanosponges. Int. J. Pharm., 2017, 531(2), 470-479.
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.072] [PMID: 28645630]
[30]
Anandam, S.; Selvamuthukumar, S. Optimization of microwave-assisted synthesis of cyclodextrin nanosponges using response surface methodology. J. Porous Mater., 2014, 21(6), 1015-1023.
[http://dx.doi.org/10.1007/s10934-014-9851-2]
[31]
Zainuddin, R.; Zaheer, Z.; Sangshetti, J.N.; Momin, M. Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. Drug Dev. Ind. Pharm., 2017, 43(12), 2076-2084.
[http://dx.doi.org/10.1080/03639045.2017.1371732] [PMID: 28845699]
[32]
Duan, J.; Freeling, J.P.; Koehn, J.; Shu, C.; Ho, R.J.Y. Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J. Pharm. Sci., 2014, 103(8), 2520-2529.
[http://dx.doi.org/10.1002/jps.24046] [PMID: 24948204]
[33]
Rajoli, R.K.R.; Back, D.J.; Rannard, S.; Freel Meyers, C.L.; Flexner, C.; Owen, A.; Siccardi, M. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin. Pharmacokinet., 2015, 54(6), 639-650.
[http://dx.doi.org/10.1007/s40262-014-0227-1] [PMID: 25523214]
[34]
Perazzolo, S.; Shireman, L.M.; Koehn, J.; McConnachie, L.A.; Kraft, J.C.; Shen, D.D.; Ho, R.J.Y. Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman Primates. J. Pharm. Sci., 2018, 107(12), 3153-3162.
[http://dx.doi.org/10.1016/j.xphs.2018.07.032] [PMID: 30121315]
[35]
Phelps, B.R.; Rakhmanina, N. Antiretroviral drugs in pediatric HIV-infected patients: Pharmacokinetic and practical challenges. Paediatr. Drugs, 2011, 13(3), 175-192.
[http://dx.doi.org/10.2165/11587300-000000000-00000] [PMID: 21500872]
[36]
Malati, C.Y.; Golin, R.; O’Brien, L.; Sugandhi, N.; Srivastava, M.; Larson, C.; Phelps, B.R. Pursuing use of optimal formulations for paediatric HIV epidemic control-a look at the use of LPV/r oral pellets and oral granules. J. Int. AIDS Soc., 2019, 22(4), e25267.
[http://dx.doi.org/10.1002/jia2.25267] [PMID: 30983152]
[37]
Ilomuanya, M.O.; Elesho, R.F.; Amenaghawon, A.N.; Adetuyi, A.O.; Velusamy, V.; Akanmu, A.S. Development of trigger sensitive hyaluronic acid/palm oil-based organogel for in vitro release of HIV/AIDS microbicides using artificial neural networks. Future Journal of Pharmaceutical Sciences, 2020, 6(1), 1.
[http://dx.doi.org/10.1186/s43094-019-0015-8] [PMID: 33241057]
[38]
Satapathy, D.; Biswas, D.; Behera, B.; Sagiri, S.S.; Pal, K.; Pramanik, K. Sunflower-oil-based lecithin organogels as matrices for controlled drug delivery. J. Appl. Polym. Sci., 2013, 129(2), 585-594.
[http://dx.doi.org/10.1002/app.38498]
[39]
Ilomuanya, M.O.; Hameedat, A.T.; Akang, E.N.; Ekama, S.O.; Silva, B.O.; Akanmu, A.S. Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis. Future Journal of Pharmaceutical Sciences, 2020, 6(1), 81.
[http://dx.doi.org/10.1186/s43094-020-00093-3] [PMID: 33241057]
[40]
Nalini, M.V.S.S.; Veni, P.R.K.; Babu, B.H. Determination of Darunavir and cobicistat simultaneously using stability indicating RP-HPLC method. Marmara Pharm. J., 2016, 20(3), 293-302.
[http://dx.doi.org/10.12991/mpj.20162036176]
[41]
Dalvadi, H.P.; Desai, S.; Jat, R.K.; Dalwadi, H. Spectrophotometric METHOD DEVELOPMENT AND VALIDATION ON atazanavir AND cobicistat IN ITS BINARY MIXTURE Solubility Enhancement techniques View project estimation of pitavastatin calcium tablet dosage form by liquid chromatography and ultraviolet spectrophotometry View project spectrophotometric METHOD DEVELOPMENT AND VALIDATION ON atazanavir AND cobicistat IN ITS BINARY MIXTURE., Available from: https://www.researchgate.net/publication/362709074
[42]
Singh, V.D.; Daharwal, S.J. Development and validation of multivariate calibration methods for simultaneous estimation of Paracetamol, Enalapril maleate and hydrochlorothiazide in pharmaceutical dosage form. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2017, 171, 369-375.
[http://dx.doi.org/10.1016/j.saa.2016.08.028] [PMID: 27569769]
[43]
Devi Singh, V.; Kumar Singh, V. Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2021, 250, 119383.
[http://dx.doi.org/10.1016/j.saa.2020.119383] [PMID: 33422867]
[44]
Williams, J.; Sayles, H.R.; Meza, J.L.; Sayre, P.; Sandkovsky, U.; Gendelman, H.E.; Flexner, C.; Swindells, S. Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients. Nanomedicine, 2013, 8(11), 1807-1813.
[http://dx.doi.org/10.2217/nnm.12.214] [PMID: 23611617]
[45]
Bailon, L.; Mothe, B.; Berman, L.; Brander, C. Novel approaches towards a functional cure of HIV/AIDS. Drugs, 2020, 80(9), 859-868.
[http://dx.doi.org/10.1007/s40265-020-01322-y] [PMID: 32436069]
[46]
Chavan, KG; Mahajan, KC; Mantry, S; Dnyaneshwar, GS; Vachane, RR; Somnath, SD Advance trend in novel formulation of nevirapine conjugated nanoemusion for antiretroviral medications. J Pharm Neg Results, 13.,
[47]
Aurobindo, M.H.U. Pharmaceutical composition of Antiretroviral. United States patent US; 2011/0104267 A1,,
[48]
Adeyeye, M.C.; Esseku, F.; Joshi, A. Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS. United States patent application US.,, 2011.
[49]
Marom, E.; Saba, K.; Rubnov, S.; Aviv, T. Amorphous form of dolutegravir. United States patent US., 2015.
[50]
Giardiello, M.; McDonald, T.; Owen, A.; Rannard, S.; Martin, P.; Smith, D. Compositions of lopinavir and ritonavir. United states patent US 9,532.979 B2,, 2017.
[51]
Medicament comprising Pharm Comb Dolutegravir Emtricitabine Tenofovir. WO2015/022351 A1,, 2015.
[52]
Giardiello, N.M.; Oliver, T.; Paul, S.; John, P. The University of Liverpool assignee. Compos Efavirenz Eur EP. B1:2753314, 2020.
[53]
Graham, T.H.; Liu, W.; Yu, T.; Zhang, Y.; Waddell, S.T.; Wai, J.S. Spirocyclic hetercycle compounds useful as HIV integrase inhibitors. US9707234B2, 2017.
[54]
Cocklin, S. Composition useful for inhibiting HIV infection. United States patent US 9920073B2, 2018.
[55]
Tamura, Y.; Sugiyama, S.; Matsumura, A.; Akiyama, T.; Tomida, Y. Nitrogen-containing tricyclic derivertives having hiv reprication inhibitory activity. TWI700284B, 2020.
[56]
Cho, A.; Link, J.; Xu, J. HIV protease inhibitor. United States patent US11318119 B2, 2022.
[57]
Woodrow, K.A.; Ball, C.; Blakney, A.; Krogstad, E.; Nie, H. Vaginal matrices: Nanofibers for contraception and prevention of HIV infection. US20140128345A1, 2016.
[58]
Zou, W.; Liu, Y.; Wang, J.; Li, H.; Liao, X. Traditional Chinese herbal medicines for treating HIV infections and AIDS. Evid. Based Complement. Alternat. Med., 2012, 2012, 1-8.
[http://dx.doi.org/10.1155/2012/950757] [PMID: 23326295]
[59]
Wu, J.A.; Attele, A.S.; Zhang, L.; Yuan, C.S. Anti-HIV activity of medicinal herbs: usage and potential development. Am. J. Chin. Med., 2001, 29(1), 69-81.
[http://dx.doi.org/10.1142/S0192415X01000083] [PMID: 11321482]
[60]
Liu, J. The use of herbal medicines in early drug development for the treatment of HIV infections and AIDS. Expert Opin. Investig. Drugs, 2007, 16(9), 1355-1364.
[http://dx.doi.org/10.1517/13543784.16.9.1355] [PMID: 17714022]
[61]
Shi, D.; Peng, Z.L. Randomised, double-blind, placebo-controlled clinical study on Qiankunning for HIV/AIDS. China J. Chin. Med., 2003, 21(9), 1472-1474.
[62]
Jian, W.; Feng-zhen, Y.; Min, Z.; Yun-hui, Z.; Yong-xiang, Z.; Ying, L.; Wei-min, L.; Fu-sheng, W.; Shu-ling, X.; Zhi-min, Y.; Yan-ming, X.; Xian-zhi, Z.; Tian-jun, I. Randomized double-blinded and controlled clinical trial on treatment of HIV/AIDS by Zhongyan-4. Chin. J. Integr. Med., 2006, 12(1), 6-11.
[http://dx.doi.org/10.1007/BF02857422] [PMID: 16571276]
[63]
Sangkitporn, S.; Shide, L.; Klinbuayaem, V.; Leenasirimakul, P.; Wirayutwatthana, N.A.; Leechanachai, P.; Dettrairat, S.; Kunachiwa, W.; Thamlikitkul, V. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian J. Trop. Med. Public Health, 2005, 36(3), 704-708.
[PMID: 16124442]
[64]
Durant, J.; Chantre, P.; Gonzalez, G.; Vandermander, J.; Halfon, P.; Rousse, B.; Guédon, D.; Rahelinirina, V.; Chamaret, S.; Montagnier, L.; Dellamonica, P. Efficacy and safety of Buxus sempervirens L. preparations (SPV30) in HIV-infected asymptomatic patients: A multicentre, randomized, double-blind, placebo-controlled trial. Phytomedicine, 1998, 5(1), 1-10.
[http://dx.doi.org/10.1016/S0944-7113(98)80052-4] [PMID: 23195692]
[65]
Bodeker, G.; Carter, G.; Burford, G.; Dvorak-Little, M. HIV/AIDS: Traditional systems of health care in the management of a global epidemic. J. Altern. Complement. Med., 2006, 12(6), 563-576.
[http://dx.doi.org/10.1089/acm.2006.12.563] [PMID: 16884348]
[66]
van den Bout-van den Beukel, C.J.P.; Koopmans, P.P.; van der Ven, A.J.A.M.; De Smet, P.A.G.M.; Burger, D.M. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab. Rev., 2006, 38(3), 477-514.
[http://dx.doi.org/10.1080/03602530600754065] [PMID: 16877262]
[67]
Holodniy, M.; Koch, J.; Mistal, M.; Schmidt, J.M.; Khandwala, A.; Pennington, J.E.; Porter, S.B. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am. J. Gastroenterol., 1999, 94(11), 3267-3273.
[http://dx.doi.org/10.1111/j.1572-0241.1999.01535.x] [PMID: 10566728]
[68]
Fischer, H.; Machen, T.E.; Widdicombe, J.H.; Carlson, T.J.S.; King, S.R.; Chow, J.W.S.; Illek, B. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J. Ethnopharmacol., 2004, 93(2-3), 351-357.
[http://dx.doi.org/10.1016/j.jep.2004.04.005] [PMID: 15234776]
[69]
Burack, J.H.; Cohen, M.R.; Hahn, J.A.; Abrams, D.I. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1996, 12(4), 386-393.
[http://dx.doi.org/10.1097/00042560-199608010-00009] [PMID: 8673548]
[70]
Mills, E.; Foster, B.C.; Heeswijk, R.; Phillips, E.; Wilson, K.; Leonard, B.; Kosuge, K.; Kanfer, I. Impact of African herbal medicines on antiretroviral metabolism. AIDS, 2005, 19(1), 95-97.
[http://dx.doi.org/10.1097/00002030-200501030-00013] [PMID: 15627040]
[71]
Available from: https://www.clinicaltrials.gov/study/NCT02140775?cond=HIV%2FAIDS&page=3&rank=22
[72]
Available from: https://www.clinicaltrials.gov/study/NCT02850276?cond=HIV%2FAIDS&page=2&rank=15
[73]
Available from: https://www.clinicaltrials.gov/study/NCT02898597?cond=HIV%2FAIDS&page=2&rank=16
[74]
Available from: https://www.clinicaltrials.gov/study/NCT02707692?cond=HIV%2FAIDS&page=2&rank=11
[75]
Available from: https://www.clinicaltrials.gov/study/NCT02291809?cond=HIV%2FAIDS&page=2&rank=14
[76]
Available from: https://www.clinicaltrials.gov/study/NCT04735445?cond=HIV%2FAIDS&page=3&rank=23
[77]
Available from: https://www.clinicaltrials.gov/study/NCT03661203?cond=HIV%2FAIDS&page=1&rank=7
[78]
Available from: https://www.clinicaltrials.gov/study/NCT05307250?cond=HIV%2FAIDS&page=3&rank=30
[79]
Available from: https://www.clinicaltrials.gov/study/NCT05423418?cond=HIV%2FAIDS&page=1&rank=9
[80]
Available from: https://www.clinicaltrials.gov/study/NCT05872659?cond=HIV%2FAIDS&page=1&rank=2